全文获取类型
收费全文 | 4220篇 |
免费 | 496篇 |
国内免费 | 61篇 |
出版年
2024年 | 11篇 |
2023年 | 87篇 |
2022年 | 110篇 |
2021年 | 245篇 |
2020年 | 233篇 |
2019年 | 225篇 |
2018年 | 223篇 |
2017年 | 140篇 |
2016年 | 129篇 |
2015年 | 205篇 |
2014年 | 307篇 |
2013年 | 280篇 |
2012年 | 237篇 |
2011年 | 274篇 |
2010年 | 192篇 |
2009年 | 157篇 |
2008年 | 177篇 |
2007年 | 206篇 |
2006年 | 185篇 |
2005年 | 125篇 |
2004年 | 127篇 |
2003年 | 114篇 |
2002年 | 106篇 |
2001年 | 67篇 |
2000年 | 37篇 |
1999年 | 32篇 |
1998年 | 34篇 |
1997年 | 47篇 |
1996年 | 23篇 |
1995年 | 35篇 |
1994年 | 42篇 |
1993年 | 33篇 |
1992年 | 30篇 |
1991年 | 22篇 |
1990年 | 29篇 |
1989年 | 17篇 |
1988年 | 13篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 19篇 |
1984年 | 43篇 |
1983年 | 28篇 |
1982年 | 22篇 |
1981年 | 12篇 |
1980年 | 11篇 |
1979年 | 19篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1974年 | 8篇 |
1971年 | 6篇 |
排序方式: 共有4777条查询结果,搜索用时 15 毫秒
101.
目的:评估解毒颗粒联合阿帕替尼治疗中晚期肝癌患者的疗效及其不良反应。方法:对2018年12月至2019年6月收治于海军军医大学第一附属医院口服解毒颗粒联合阿帕替尼的27例肝癌患者的临床资料进行回顾性研究。无法切除或复发的中晚期肝癌患者被纳入研究,给予解毒颗粒联合阿帕替尼治疗直至疾病进展或不可耐受其毒副反应,随访观察治疗效果、生存期、炎症因子指标及不良反应。结果:治疗后完全缓解(CR)4例(14.81%),部分缓解(PR)4例(14.81%),稳定(SD)8例(29.63%),进展(PD)11名患者(40.74%),疾病控制率(DCR)为59.26%(16/27),客观缓解率(ORR)为29.63%(8/27)。中位无进展生存期(PFS)为3.630个月,中位总生存期(OS)为13.667个月。常见的不良反应是高血压59.26%(16/27)、蛋白尿59.26%(16/27)、腹泻74.07%(20/27)以及手足综合征62.96%(17/27)。治疗后炎症因子指标中C反应蛋白、白介素2水平下降,存在统计学差异(P0.05)。结论:解毒颗粒联合阿帕替尼治疗中晚期肝癌安全、有效,可降低患者炎症反应,不良反应可耐受。 相似文献
102.
摘要 目的:探讨外周血中性粒细胞与淋巴细胞比值(NLR)在特发性膜性肾病(IMN)中的临床及病理价值。方法:收集2017年1月至2019年12月确诊为IMN患者221例作为IMN组,将2019年7月至2019年9月体检且尿常规和肾功能指标正常的87例健康体检者作为正常对照组,计算每个研究对象的NLR值,比较两组间NLR值的差异。记录IMN患者的血生化指标及患者的肾脏病理分期及纤维化程度,并且根据MDRD公式计算肾小球滤过率(eGFR),分析NLR与IMN患者的血生化指标及病理特征的相关性。ROC曲线分析外周血NLR评估IMN患者肾间质纤维化的敏感性和特异性。结果:IMN组外周血NLR值高于对照组,差异有统计学意义(P<0.05)。外周血NLR值与IMN患者年龄和肾间质纤维化有关联(P均<0.05),但与IMN患者性别及肾脏病理分期无关联(P均>0.05)。IMN外周血NLR值与IMN患者hs-CRP、SCr、BUN呈正相关(P<0.05),与eGFR呈负相关(P<0.05),与ESR、UA、TP、Alb、24小时蛋白尿定量均无相关性(P均>0.05)。不同程度肾间质纤维化的IMN患者外周血NLR值不同,差异有统计学意义(P<0.05),且肾间质纤维化程度在1、2、3级时,纤维化程度越重,NLR值越大;3个级别间两两比较,差异均有统计学意义(P均<0.05)。外周血NLR值预测IMN患者肾间质纤维化的ROC曲线下面积为0.715[95%CI(0.626,0.803)],其截断值为1.858时,灵敏度为68.6%,特异度为66.7%。结论:外周血NLR可作为IMN肾脏功能水平的一个有效评价指标,且与IMN患者肾间质纤维化有关,可作为判断肾间质纤维化的参考指标。 相似文献
103.
摘要 目的:探讨慢性乙型肝炎(CHB)患者血清白细胞介素-17A (IL-17A)、高尔基体蛋白73(GP73)水平与肝功能指标及病情严重程度的关系。方法:选取2018年10月至2019年10月于青海大学附属医院就诊的CHB患者93例作为研究对象(CHB组),另选取同时期于我院体检的健康志愿者33例作为对照组。比较不同病情严重程度、不同乙型肝炎e抗原(HbeAg)表达的CHB患者IL-17A、GP73水平及肝功能相关指标[丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、白蛋白、总胆红素(TBiL)]的差异,并分析IL-17A、GP73水平与患者病情严重程度及肝功能相关指标的相关性。结果:CHB组中轻度、中度、重度患者血清IL-17A、GP73、ALT、AST及TBiL水平均高于对照组,白蛋白水平低于对照组(P<0.05),并且随着CHB患者病情严重程度的加重其血清中IL-17A、GP73、ALT、AST及TBiL水平逐渐升高,白蛋白水平逐渐降低(P<0.05)。CHB组HbeAg阴性患者血清中的IL-17A、GP73、ALT及AST水平均明显高于HbeAg阳性患者(P<0.05),而白蛋白和TBiL水平无明显差异(P>0.05)。CHB患者血清IL-17A、GP73均与ALT、AST及TBiL呈正相关,与白蛋白呈负相关,与患者病情严重程度呈正相关(P<0.05)。结论:CHB患者血清中IL-17A、GP73水平明显升高,且与患者病情严重程度及肝功能相关指标呈明显相关性,临床中可联合检测用于患者病情评估及预后监测。 相似文献
104.
丁雨 《基因组学与应用生物学》2020,39(2):914-920
本研究考察了秋葵籽油对高强度运动所致肝损伤的保护作用及机制。研究显示,对昆明小鼠灌胃不同剂量(10 mg/kg,20 mg/kg和50 mg/kg)的秋葵籽油4周后,秋葵籽油以剂量依赖性方式提高了小鼠的力竭游泳时间(p<0.05)。秋葵籽油降低了小鼠血清乳酸和尿素氮水平,并升高了血清游离脂肪酸和肝糖原水平(p<0.05)。秋葵籽油以剂量依赖性方式提高了小鼠肝脏组织中SOD、CAT和GSH-Px活性,并抑制了MDA的合成(p<0.05)。秋葵籽油抑制了力竭游泳诱导的小鼠血清CK、AST和ALT水平及肝脏组织NO水平的升高(p<0.05)。此外,苏木精和伊红(HE)染色证实了秋葵籽油减轻了力竭游泳诱导的肝脏病理改变。因此,本研究初步结论表明,在高强度运动过程中,秋葵籽油可通过抑制乳酸和尿素氮的积累、增加脂肪动员、降低糖原消耗、减弱氧化应激损伤等多种途径来对肝脏发挥保护作用。 相似文献
105.
《Reports of Practical Oncology and Radiotherapy》2020,25(6):987-993
AimThis study reports a single-institutional experience treating liver metastases with stereotactic body radiation therapy (SBRT).Materials and methods107 patients with 169 lesions were assessed to determine factors predictive for local control, radiographic response, and overall survival (OS). Machine learning techniques, univariate analysis, and the Kaplan-Meier method were utilized.ResultsPatients were treated with a relatively low median dose of 30 Gy in 3 fractions. Fractions were generally delivered once weekly. Median biologically effective dose (BED) was 60 Gy, and the median gross tumor volume (GTV) was 12.16 cc. Median follow-up was 7.36 months. 1-year local control was 75% via the Kaplan-Meier method. On follow-up imaging, 43%, 40%, and 17% of lesions were decreased, stable, and increased in size, respectively. 1-year OS was 46% and varied by primary tumor, with median OS of 34.3, 25.1, 12.5, and 4.6 months for ovarian, breast, colorectal, and lung primary tumors, respectively. Breast and ovarian primary patients had better OS (p < 0.0001), and lung primary patients had worse OS (p = 0.032). Higher BED values, the number of hepatic lesions, and larger GTV were not predictive of local control, radiographic response, or OS. 21% of patients suffered from treatment toxicity, but no grade ≥3 toxicity was reported.ConclusionRelatively low-dose SBRT for liver metastases demonstrated efficacy and minimal toxicity, even for patients with large tumors or multiple lesions. This approach may be useful for patients in whom higher-dose therapy is contraindicated or associated with high risk for toxicity. OS depends largely on the primary tumor. 相似文献
106.
107.
《Reports of Practical Oncology and Radiotherapy》2020,25(3):376-381
PurposeWe investigated the feasibility of robust optimization for volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) for liver cancer in comparison with planning target volume (PTV)-based optimized plans. Treatment plan quality, robustness, complexity, and accuracy of dose delivery were assessed.MethodsTen liver cancer patients were selected for this study. PTV-based optimized plans with an 8-mm PTV margin and robust optimized plans with an 8-mm setup uncertainty were generated. Plan perturbed doses were evaluated using a setup error of 8 mm in all directions from the isocenter. The dosimetric comparison parameters were clinical target volume (CTV) doses (D98%, D50%, and D2%), liver doses, and monitor unit (MU). Plan complexity was evaluated using the modulation complexity score for VMAT (MCSv).ResultsThere was no significant difference between the two optimizations with respect to CTV doses and MUs. Robust optimized plans had a higher liver dose than did PTV-based optimized plans. Plan perturbed dose evaluations showed that doses to the CTV for the robust optimized plans had small variations. Robust optimized plans were less complex than PTV-based optimized plans. Robust optimized plans had statistically significant fewer leaf position errors than did PTV-based optimized plans.ConclusionsComparison of treatment plan quality, robustness, and plan complexity of both optimizations showed that robust optimization could be feasibile for VMAT of liver cancer. 相似文献
108.
Durgesh K. Dwivedi Gopabandhu Jena Vinod Kumar 《Journal of biochemical and molecular toxicology》2020,34(6)
The present study was designed to investigate the hepatoprotective potential of dimethyl fumarate (DMF) against thioacetamide (TAA)‐induced liver damage. Wistar rats were treated with DMF (12.5, 25, and 50 mg/kg/day, orally) and TAA (200 mg/kg intraperitoneally, every third day) for 6 consecutive weeks. TAA exposure significantly reduced body weight, increased liver weight and index, and intervention with DMF did not ameliorate these parameters. DMF treatment significantly restored TAA‐induced increase in the levels of aspartate aminotransferase, alanine aminotransferase, γ‐glutamyl transferase, total bilirubin, uric acid, malondialdehyde, reduced glutathione, and histopathological findings such as inflammatory cell infiltration, deposition of collagen, necrosis, and bridging fibrosis. DMF treatment significantly ameliorated TAA‐induced hepatic stellate cell activation, increase in inflammatory cascade markers (NACHT, LRR, and PYD domains‐containing protein 3; NLRP3, apoptosis‐associated speck like protein containing a caspase recruitment domain; ASC, caspase‐1, nuclear factor‐kappa B; NF‐κB, interleukin‐6), fibrogenic makers (α‐smooth muscle actin; ɑ‐SMA, transforming growth factor; TGF‐β1, fibronectin, collagen 1) and antioxidant markers (nuclear factor (erythroid‐derived 2)‐like factor 2; Nrf2, superoxide dismutase‐1; SOD‐1, catalase). The present findings concluded that DMF protects against TAA‐induced hepatic damage mediated through the downregulation of inflammatory cascades and upregulation of antioxidant status. 相似文献
109.
Ju Zhou Qing Lan Wu Li Lin Yang Jing You Yan‐Mei Zhang Wei Ni 《Cell biology international》2020,44(1):108-116
To investigate the roles of tripartite motif containing 52 (TRIM52) in human hepatic fibrosis in vitro, human hepatic stellate cell line LX‐2 cells were transfected with hepatitis B virus (HBV) replicon to establish HBV‐induced fibrosis in LX‐2 cells, and then treated with small interfering RNA‐mediated knockdown of TRIM52 (siTRIM52). LX‐2 cells without HBV replicon transfection were treated with lentiviruses‐mediated overexpression of TRIM52 and phosphatase magnesium dependent 1A (PPM1A). Fibrosis response of LX‐2 cells were assessed by the production of hydroxyproline (Hyp) and collagen I/III, as well as protein levels of α‐smooth muscle actin (α‐SMA). PPM1A and phosphorylated (p)‐Smad2/3 were measured to assess the mechanism. The correlation between TRIM52 and PPM1A was determined using co‐immunoprecipitation, and whether and how TRIM52 regulated the degradation of PPM1A were determined by ubiquitination assay. Our data confirmed HBV‐induced fibrogenesis of LX‐2 cells, as evidenced by significant increase in Hyp and collagen I/III and α‐SMA, which was associated with reduction of PPM1A and elevation of transforming growth factor‐β (TGF‐β), p‐Smad2/3, and p‐Smad3L. However, those changes induced by HBV were significantly attenuated with additional siTRIM52 treatment. Similar to HBV, overexpression of TRIM52 exerted promoted effect in the fibrosis of LX‐2 cells. Interestingly, TRIM52 induced the fibrogenesis of LX‐2 cells and the activation of TGF‐β/Smad pathway were significantly reversed by PPM1A overexpression. Furthermore, our data confirmed TRIM52 as a deubiquitinase that influenced the accumulation of PPM1A protein, and subsequently regulated the fibrogenesis of LX‐2 cells. TRIM52 was a fibrosis promoter in hepatic fibrosis in vitro, likely through PPM1A‐mediated TGF‐β/Smad pathway. 相似文献
110.
Ming‐Yuan Du Jia‐Xi Duan Chen‐Yu Zhang Hui‐Hui Yang Xin‐Xin Guan Wen‐Jing Zhong Yan‐Zhe Liu Zi‐Ming Li Yu‐Rui Cheng Yong Zhou Cha‐Xiang Guan 《Cell biology international》2020,44(1):98-107
Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by excessive deposition of extracellular matrix (ECM) and chronic inflammation with limited therapeutic options. Psoralen, a major active component extracted from Psoralea corylifolia L. seed, has several biological effects. However, the role of psoralen in IPF is still unclear. Here, we hypothesized that psoralen played an essential role in IPF in the inhibition of fibroblast proliferation and inflammatory response. A murine model of IPF was established by injecting bleomycin (BLM) intratracheally, and psoralen was administered for 14 days from the 7th to 21st day after BLM injection. Our results demonstrated that psoralen treatment reduced body weight loss and improved the survival rate of mice with IPF. Histological and immunofluorescent examination showed that psoralen alleviated BLM‐induced lung parenchymal inflammatory and fibrotic alteration. Furthermore, psoralen inhibited proliferation and collagen synthesis of mouse fibroblasts and partially reversed BLM‐induced expression of α‐smooth muscle actin at both the tissue and cell level. Moreover, psoralen decreased the expression of transforming growth factor‐β1, interleukin‐1β, and tumor necrosis factor‐α in the lungs of BLM‐stimulated mice. Our results reveale for the first time that psoralen exerts therapeutic effects against IPF in a BLM‐induced murine model. 相似文献